Everest Medicines Limited (1952.HK)

HKD 50.8

(3.15%)

Total Assets Summary of Everest Medicines Limited

Everest Medicines Limited's latest annual total assets in 2023 was 5.77 Billion CNY , down -12.73% from previous year.
Everest Medicines Limited's latest quarterly total assets in 2024 Q1 was - CNY , down -100.0% from previous quarter.
Everest Medicines Limited reported annual total assets of 6.61 Billion CNY in 2022, down -0.47% from previous year.
Everest Medicines Limited reported annual total assets of 6.64 Billion CNY in 2021, down -11.12% from previous year.
Everest Medicines Limited reported quarterly total assets of 5.77 Billion CNY for 2023 Q3, down -2.05% from previous quarter.
Everest Medicines Limited reported quarterly total assets of 5.77 Billion CNY for 2023 FY, down -12.73% from previous quarter.

Annual Total Assets Chart of Everest Medicines Limited (2023 - 2018)

Historical Annual Total Assets of Everest Medicines Limited (2023 - 2018)

Year	Total Assets	Total Assets Growth
2023	5.77 Billion CNY	-12.73%
2022	6.61 Billion CNY	-0.47%
2021	6.64 Billion CNY	-11.12%
2020	7.47 Billion CNY	249.9%
2019	2.13 Billion CNY	195.5%
2018	723.17 Million CNY	0.0%

Year	Total Assets	Total Assets Growth
2024 Q1	- CNY	-100.0%
2023 Q3	5.77 Billion CNY	-2.05%
2023 FY	5.77 Billion CNY	-12.73%
2023 Q4	5.77 Billion CNY	0.0%
2023 Q2	5.89 Billion CNY	0.0%
2023 Q1	5.89 Billion CNY	-10.9%
2022 Q4	6.61 Billion CNY	0.0%
2022 Q3	6.61 Billion CNY	11.68%
2022 Q2	5.92 Billion CNY	0.0%
2022 Q1	5.92 Billion CNY	-10.88%
2022 FY	6.61 Billion CNY	-0.47%
2021 Q3	6.64 Billion CNY	-13.38%
2021 Q2	7.67 Billion CNY	0.0%
2021 Q1	7.67 Billion CNY	2.61%
2021 FY	6.64 Billion CNY	-11.12%
2021 Q4	6.64 Billion CNY	0.0%
2020 Q4	7.47 Billion CNY	0.0%
2020 Q1	2.15 Billion CNY	0.0%
2020 Q3	7.47 Billion CNY	0.0%
2020 Q2	- CNY	-100.0%
2020 FY	7.47 Billion CNY	249.9%
2019 FY	2.13 Billion CNY	195.5%
2019 Q1	- CNY	0.0%
2018 FY	723.17 Million CNY	0.0%

Peer Total Assets Comparison of Everest Medicines Limited

Name	Total Assets	Total Assets Difference
Uni-Bio Science Group Limited	409.99 Million HKD	-1308.021%
CK Life Sciences Int'l., (Holdings) Inc.	11.24 Billion HKD	48.675%